What They're Saying About "Most Favored Nations" Proposals

Florida and national voices warn that foreign-based pricing proposals like HB 697 could limit access to care.

Patients, providers, business leaders, and community organizations across Florida and nationwide have weighed in on similar "Most Favored Nation" proposals, and are raising concerns about policies that tie U.S. drug reimbursement to prices set in foreign health systems. The following statements reflect a broad and bipartisan set of urging policymakers to focus on patient-first solutions that lower costs without sacrificing access, choice, or timely care.

"In the United States, nearly 90% of all medicines launched globally between 2012 and 2021 are available to patients. Compare that to 48% in the United Kingdom, 24% in Australia, and just 21% in Canada. These countries, often used as reference points in foreign price-setting models, limit the treatments patients can receive and force them to wait months or years longer for new therapies. In oncology, where time is irreplaceable, those delays are not policy abstractions; they are life-altering barriers."

– Michelle Flowers, Founder of Oncology Managers of Florida

"Price controls imposed by governments of other countries have made it extremely difficult for some patients to access their medicines…On average, Canadian and French patients gain access to new cancer and rare disease medicines almost a year and a half later than U.S. patients. And in 2019, nearly 1 in 2 European patients reported experiencing medicine shortages either personally or by a family member. This immediately impacted the patients' health — with 42% of those surveyed reporting delays in care or therapy."

– Skylar Zander, State Director of Americans for Prosperity-Florida

"If we embrace an MFN-type reference pricing policy, it means embracing health care rationing as well. This type of rationing in many European countries has not only resulted in access issues but has also translated into higher mortality rates for chronic diseases, such as cancer."

– Alliance for Aging Research

"Florida's competitive advantage has always been its commitment to free-market principles, innovation, and patient choice. Importing pricing models from centralized health systems that operate very differently from ours risks undermining those strengths and could make Florida less attractive for investment, growth, and job creation."

- Julio Fuentes, President & CEO of the Florida State Hispanic Chamber of Commerce

"High drug prices in the United States must be addressed, but MFN would impose a nationwide, mandatory experiment on people with cancer and their providers that could significantly restrict patients' access to care – without any evidence that it will actually cut care costs."

– American Society of Clinical Oncology

"Time and time again, across numerous market sectors, artificially setting prices using foreign reference pricing has been unsuccessful. And when applied to pharmaceuticals, it could ultimately harm patients and undermine the administration's important goal of 'Making America Healthy Again'."

– Healthy Men

"CMS also acknowledged that 'beneficiaries may experience access to care impacts,' including difficulty finding providers and extended traveling to seek care. These are alarming forecasts about the future impact of these proposals if applied to Medicaid, which we believe should sufficiently deter members of Congress from advancing this proposal."

– Coalition of State Rheumatology Organizations